Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,429 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Digestive System Neoplasms Clear all

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more

Conditions: Pancreatic Cancer
Interventions: Volociximab, Gemcitabine; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Solid Pancreatic Mass Lesions, Malignant Neoplasm of Pancreas
Interventions: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions: Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Colorectal Cancer, Precancerous Condition
Interventions: celecoxib, placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years to 14 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Honolulu, Hawaii

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: filgrastim, pegylated liposomal doxorubicin hydrochloride; Biological · Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Interventions: HyperSight Imaging; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions: LMB-9 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions: Semi Quantitative Food Frequency Questionnaire (SQFFQ); Behavioral
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2035
U.S. locations: 2
States / cities: Denver, Colorado • Chicago, Illinois

Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7
Interventions: Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab, Ribavirin; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions: Carfilzomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions: Acupuncture, Sham Acupuncture; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Gastrointestinal Neoplasms
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cachexia, Weight Loss, Gastrointestinal Cancer
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more

Conditions: Hepatocellular Carcinoma
Interventions: TheraSphere®, Sorafenib; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Colon Adenocarcinoma
Interventions: Carbon C 14 Oxaliplatin, Oxaliplatin; Drug
Lead sponsor: Edward Kim; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Comparison of a Novel 22-gauge Core Biopsy Needle

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Evaluation of Improved Onboard Patient Imaging

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Pancreas Registry and High Risk Registry

Utility of OverStitch Sx After ESD

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy